Your browser doesn't support javascript.
loading
Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta-analyses.
Yoshihara, T; Shinzaki, S; Iijima, H; Tsujii, Y; Hayashi, Y; Takehara, T.
Affiliation
  • Yoshihara T; Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Shinzaki S; Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Iijima H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan.
  • Tsujii Y; Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Hayashi Y; Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Takehara T; Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
J Gastroenterol Hepatol ; 38(5): 830-832, 2023 05.
Article in En | MEDLINE | ID: mdl-36866596
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Ustekinumab Limits: Humans Language: En Journal: J Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Document type: Article Affiliation country: Japón
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Ustekinumab Limits: Humans Language: En Journal: J Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Document type: Article Affiliation country: Japón